Skip to content

Effect of Nigella Sativa on Nonalcoholic Steatohepatitis and Steatosis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02307344
Acronym
NASH NAFLD
Enrollment
100
Registered
2014-12-04
Start date
2015-01-31
Completion date
2017-01-31
Last updated
2014-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Steatosis, Nonalcoholic Steatohepatitis

Brief summary

The investigators hypothesize that Nigella Sativa will have an effect on Nonalcoholic Steatohepatitis and Liver Steatosis by enhancing lipophagy in the liver tissue.

Interventions

DIETARY_SUPPLEMENTNigella Sativa
DIETARY_SUPPLEMENTPlacebo

Capsules that contain a placebo but look like the Nigella Sativa capsules

Sponsors

Hillel Yaffe Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients suffering from Steatohepatitis * Patients suffering from Liver Steatosis

Exclusion criteria

* Patients suffering from viral hepatitis * Patients with HIV infection * Patients suffering from Wilsons Disease

Design outcomes

Primary

MeasureTime frameDescription
Effect of Nigella Sativa on Liver Triglyceride ConcentrationOne yearThe difference in change in the average liver triglyceride concentration will be measured by MRI Spectroscopy between the Nigella Sativa arm and the placebo arm, at start and end of the study.

Secondary

MeasureTime frameDescription
Effect of Nigella Sativa on Improvement in NASH Activity IndexOne yearImprovement in Nash activity Index will be measured by the NAFLD Activity Score.
Effect of Nigella Sativa on Fibrosis StagingOne yearMicroscopic examination of two liver biopsies at start and end of the study, to determine fibrosis staging.

Countries

Israel

Contacts

Primary ContactSaif Abu Mouch, MD
saif@hy.health.gov.il972-506-246-966

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026